• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.
By BRUCE KAMICH
Jan 31, 2020 | 08:25 AM EST
Stocks quotes in this article: ABBV, BMY, AGN

During Thursday's "Mad Money" program host Jim Cramer said that in the battle of big pharma there are a lot of great names to choose from, but his favorites are AbbVie Inc. (ABBV) and Bristol-Myers Squibb (BMY) . If forced to choose between these two companies Cramer said he'd invest in AbbVie, which has slightly higher growth, though his Action Alerts PLUS charitable trust has positions in both companies. 

There are a lot of things to like about AbbVie, Cramer said. The company is a leader in the treatment of migraines, and with the acquisition of Allergan (AGN) AbbVie will add a number of valuable franchises, including Botox. Cramer said shares of AbbVie currently trade for a steal, at just 9x forward earnings.

We looked at the charts of BMY earlier this month. Let's check out the charts of AbbVie here on Friday.

In this daily bar chart of ABBV, below, we can see that prices made a low back in August and rallied to a high in December. Prices have corrected lower for much of the month of January, closing below the cresting 50-day moving average line and getting closer to the rising 200-day moving average line. The daily On-Balance-Volume (OBV) line moved higher from August to tell us that buyers of ABBV were acting more aggressive. However, the OBV line has turned lower in January to suggest increased selling or liquidation. The Moving Average Convergence Divergence (MACD) oscillator peaked in November and crossed to a take-profits sell signal. Now the MACD oscillator is crossing the zero line for an outright sell signal.

In this weekly Japanese candlestick chart of ABBV, below, we can see the price action over the past three years. Prices were nearly cut in half in a decline from late 2017/early 2018 to around the middle of 2019. Prices have rallied above the 40-week moving average line, which now has a positive slope. The weekly OBV line made lows in August and September and rallied into late 2019. The MACD oscillator on this longer time frame turned bullish in November but has since crossed to the downside for a take-profits sell signal.

In this first Point and Figure chart of ABBV, below, we used daily data to plot the X's and O's that make the chart. The price action suggests some liquidation (selling) and a potential downside price target around $76, which would mean a test of the 200-day moving average line. The volume-by-price bars on the left scale suggest good support in the area.

In this second Point and Figure chart of ABBV, we used weekly close-only price data and here the software is projecting a potential longer-term price target of around $136.

Bottom line strategy: Our weekly Point and Figure chart (above) suggests that ABBV has plenty of longer-term potential, but our daily chart suggests we may see some further price weakness before a new rally gets underway. Traders should wait for a reversal pattern on the weekly candle chart before going long or adding to longs.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Healthcare | Pharmaceuticals | Mad Money

More from Stocks

Melvin Capital's Demise Presents a Beauty of an Opportunity

Brad Ginesin
May 22, 2022 1:20 PM EDT

The top holder in several companies, the hedge fund's abrupt liquidation has contributed to weakness.

I'm Organizing a Bottom-Fishing Expedition

Bret Jensen
May 22, 2022 11:00 AM EDT

It is easy to see the value of this retail play.

Here's the Secret to Market Timing

James "Rev Shark" DePorre
May 21, 2022 10:00 AM EDT

You've probably been told timing the market is futile, but here's a way to make it possible -- if you're willing to do the work.

It's Official: That Hairy Animal With Claws and Sharp Teeth Is a Bear

James "Rev Shark" DePorre
May 20, 2022 4:31 PM EDT

Along with the media proclamation of a bear market, we have some improvement in the charts of many smaller stocks, but ...

Applied Materials Slips on Miss: Where Will the Chips May Fall

Bruce Kamich
May 20, 2022 1:00 PM EDT

Let's see what the charts say.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An interesting chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login